Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CCR3 | P51677 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31228277 | 1.00 | CYP1A2 (0.46) | CYP1A2CYP2A6TDO2BACE1AHR | |
| SCHEMBL18733501 | 0.92 | CYP1A2 (0.46) | CYP1A2CYP2A6TDO2BACE1AHR | |
| SCHEMBL31556379 | 0.75 | CYP2A6 (0.46) | CYP1A2CYP2A6BACE1AHRL3MBTL1 | |
| SCHEMBL1536308 | 0.75 | CYP2A6 (0.46) | CYP1A2CYP2A6BACE1AHRL3MBTL1 | |
| SCHEMBL16637560 | 0.75 | CYP2A6 (0.46) | CYP2A6AHR | |
| SCHEMBL3698199 | 0.75 | CYP1A2 (0.54) | CYP1A2CYP2A6BACE1 | |
| SCHEMBL6562601 | 0.74 | CYP1A2 (0.77) | CYP1A2CYP2A6BACE1AHRL3MBTL1 | |
| SCHEMBL30366405 | 0.74 | CYP1A2 (0.77) | CYP1A2CYP2A6BACE1AHRL3MBTL1 | |
| SCHEMBL1412043 | 0.73 | CYP2A6 (0.52) | CYP1A2CYP2A6L3MBTL1ACHE | |
| Hydrochloric Acid SCHEMBL6435272 | 0.73 | CYP2A6 (0.45) | CYP2A6BACE1AHRL3MBTL1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113923988-B | Substituted arylmethyl ureas and heteroarylmethyl ureas, analogs thereof, and methods of using the same | 爱彼特生物制药公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| EP-3893645-B1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2024-04-17 | — | — | EP | disclosed |
| US-20230045421-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-02-09 | — | — | US | disclosed |
| CN-113923988-A | Substituted arylmethyl and heteroarylmethyl ureas, analogs thereof, and methods of using the same | 爱彼特生物制药公司 | 2022-01-11 | — | — | CN | disclosed |
| EP-3893645-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2021-10-20 | — | — | EP | disclosed |
| WO-2020123674-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-06-18 | — | — | WO | disclosed |
| US-8796458-B2 | Cyclohexylamine isoquinolone derivatives | SANOFI (FR) | 2014-08-05 | — | — | US | disclosed |
| US-8748614-B2 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-20100105650-A1 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI-AVENTIS (FR) | 2010-04-29 | — | — | US | disclosed |
| US-7678803-B2 | Heat Shock Protein-90 inhibitors; Antiproliferative agents; cancer, inflammation, arthritis, angiogenesis, viral, fungal and malaria infections; 1-(isoquinoline, quinazoline or pyrimidino(3,2-d)pyridine-substituted)-4,5,6,7-tetrahydroindol-4-ones or 4,5,6,7-pyrazol-4-ones | SERENEX, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20100063025-A1 | Substituted isoquinoline and isoquinolinone derivatives as inhibitors of RHO-Kinase | SANOFI-AVENTIS (FR) | 2010-03-11 | — | — | US | disclosed |
| US-20100056568-A1 | Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives | SANOFI-AVENTIS (FR) | 2010-03-04 | — | — | US | disclosed |
| US-20100056518-A1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-03-04 | — | — | US | disclosed |
| EP-2069325-A2 | ISOQUINOLINE, QUINAZOLINE AND PHTHALAZINE DERIVATIVES | Serenex, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
| US-20080242699-A1 | Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase inhibitors; Hypotensive agents; 6-(4-Amino-cyclohexyloxy)-2-(4-methoxy-benzyl)-7-propyl-2H-isoquinolin-1-one | SANOFI-AVENTIS (FR) | 2008-10-02 | — | — | US | disclosed |
| US-20080070935-A1 | Isoquinoline, Quinazoline and Phthalazine Derivatives | ESANEX, INC. | 2008-03-20 | — | — | US | disclosed |
| WO-2008024977-A2 | ISOQUINOLINE, QUINAZOLINE AND PHTHALAZINE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063025-A1 | Substituted isoquinoline and isoquinolinone derivatives as inhibitors of RHO-Kinase | ROCK1, MYLK, ROCK2 | CYP1A2 1586/4885CYP2A6 2956/4885TDO2 2711/4885 |
| US-20100056568-A1 | Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives | MYLK2, MYLK, MYLK3 | CYP1A2 2598/4885CYP2A6 3052/4885TDO2 3980/4885 |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | MYLK2, MYLK, RHOT2 | CYP1A2 2280/4885CYP2A6 2790/4885TDO2 4611/4885 |
| US-20080242699-A1 | Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase inhibitors; Hypotensive agents; 6-(4-Amino-cyclohexyloxy)-2-(4-methoxy-benzyl)-7-propyl-2H-isoquinolin-1-one | MYLK, MYLK2, ROCK1 | CYP1A2 2205/4885CYP2A6 2894/4885TDO2 3475/4885 |
| US-20100105650-A1 | Substituted isoquinoline and isoquinolinone derivatives | MYLK2, MYLK, MYLK3 | CYP1A2 1393/4885CYP2A6 2896/4885TDO2 3357/4885 |
| US-20080070935-A1 | Isoquinoline, Quinazoline and Phthalazine Derivatives | H1-5, NDUFS5, IL5 | CYP1A2 396/4885CYP2A6 1563/4885TDO2 3069/4885 |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | CYP1A2 4149/4885CYP2A6 3954/4885TDO2 3655/4885 |
| US-20230045421-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | HAVCR2, HMBS, AHCY | CYP1A2 563/4885CYP2A6 325/4885TDO2 2687/4885 |
| US-20100056518-A1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLONE DERIVATIVES | MYLK, MYLK2, MYLK3 | CYP1A2 3246/4885CYP2A6 3268/4885TDO2 3960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.